Literature DB >> 30132035

SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.

Christoph Wanner1, Nikolaus Marx2.   

Abstract

Individuals with diabetes mellitus exhibit an increased propensity to develop cardiovascular disorders such as coronary artery disease, stroke and heart failure. Over recent decades, numerous cardiovascular outcome trials in individuals with type 2 diabetes have been published, with data showing a reduction of cardiovascular morbidity and mortality by sodium-glucose cotransporter 2 (SGLT2) inhibitors. These results not only provide novel therapeutic options for this high-risk population but also advance our current understanding of cardiovascular risk reduction in diabetes. The current overview article summarises these aspects and discusses future treatment strategies with SGLT2 inhibitors in diabetic and non-diabetic individuals with chronic kidney disease, liver disease and heart failure.

Entities:  

Keywords:  Diabetes mellitus; Diabetic kidney disease; Heart failure; Non-alcoholic fatty liver disease; Non-diabetic chronic kidney disease; Review

Mesh：

Substances：

Year:  2018        PMID： 30132035     DOI： 10.1007/s00125-018-4678-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


  39 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

Review 3.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

4.  Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.

Authors:  Thaissa Dantas Pessoa; Luciene Cristina Gastalho Campos; Luciene Carraro-Lacroix; Adriana C C Girardi; Gerhard Malnic
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

5.  Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

Review 6.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors:  Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal:  Circulation       Date:  2016-07-28       Impact factor: 29.690

Review 7.  Diabetes Mellitus and Heart Failure.

Authors:  Michael Lehrke; Nikolaus Marx
Journal:  Am J Cardiol       Date:  2017-05-30       Impact factor: 2.778

8.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

Authors:  Giovanni Targher; Christopher D Byrne; Amedeo Lonardo; Giacomo Zoppini; Corrado Barbui
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

Review 10.  Current and future pharmacological therapies for NAFLD/NASH.

Authors:  Yoshio Sumida; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2017-12-16       Impact factor: 7.527
View more
  16 in total

1.  The bark giving diabetes therapy some bite: the SGLT inhibitors.

Authors:  Sally M Marshall
Journal:  Diabetologia       Date:  2018-10       Impact factor: 10.122

2.  Heart failure and diabetes: management and open issues.

Authors:  K Schütt; N Marx
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

3.  Glycaemic Control in Diabetes.

Authors:  D Müller-Wieland; J Brandts; M Verket; N Marx; K Schütt
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Evaluated Glomerular Filtration Rate Is Associated With Non-alcoholic Fatty Liver Disease: A 5-Year Longitudinal Cohort Study in Chinese Non-obese People.

Authors:  Ji Cen; Yong Han; Yufei Liu; Haofei Hu
Journal:  Front Nutr       Date:  2022-06-16

Review 5.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

6.  Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.

Authors:  Yujin Shin; Ji Hye Moon; Ho Jun Chin; Ele Ferrannini; Soo Lim
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

7.  Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.

Authors:  Matthias Rau; Kirsten Thiele; Niels-Ulrik Korbinian Hartmann; Alexander Schuh; Ertunc Altiok; Julia Möllmann; András P Keszei; Michael Böhm; Nikolaus Marx; Michael Lehrke
Journal:  Cardiovasc Diabetol       Date:  2021-01-07       Impact factor: 9.951

8.  Cardioprotective effects of short-term empagliflozin treatment in db/db mice.

Authors:  Bernhard Radlinger; Florian Hornsteiner; Sabrina Folie; Willi Salvenmoser; Bernhard J Haubner; Thomas Schuetz; Simone Haas; Claudia Ress; Timon E Adolph; Karin Salzmann; Bernhard Weiss; Herbert Tilg; Susanne Kaser
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

9.  Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.

Authors:  Peter Kolkhof; Elke Hartmann; Alexius Freyberger; Mira Pavkovic; Ilka Mathar; Peter Sandner; Karoline Droebner; Amer Joseph; Jörg Hüser; Frank Eitner
Journal:  Am J Nephrol       Date:  2021-06-10       Impact factor: 3.754

Review 10.  SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review.

Authors:  Christopher El Mouhayyar; Ruba Riachy; Abir Bou Khalil; Asaad Eid; Sami Azar
Journal:  Int J Endocrinol       Date:  2020-02-29       Impact factor: 3.257
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.